Finding The Value In Shifting R&D Models
This article was originally published in The Pink Sheet Daily
Executive Summary
Consultancy McKinsey & Co. is optimistic about the future of R&D within the pharma industry, but says certain aspects of the organizations need to shift – making the companies leaner and more productive – to maintain the industry’s leadership position.
You may also be interested in...
Deals Of The Week’s Takeaway From PSA: Optimism With Aches
The federal government is on the verge of a shutdown and the Affordable Care Act is creating jitters across every corner of the health care system, but the tone at last week’s 23rd annual Pharmaceutical Strategy Conference was surprisingly optimistic, even regarding vulnerabilities at the core of biopharma’s well-being: the quality of its R&D, FDA predictability and its commercial model.
Building A Fully Integrated Biotech Company: What It Takes
A typical mature biotech company evolves over four discrete stages – from the initial discovery stage through the preclinical and early clinical stage, then to the late clinical trials and commercial build-out – before it becomes a fully integrated biotech company. The final transition is a make-or-break scenario for any biotech company, and high-quality marketed products alone don’t guarantee a successful transformation.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.